NEW YORK (GenomeWeb) – Second Genome today announced a deal with Pfizer to conduct a large microbiome observational study to find out more about obesity and metabolic diseases.

The study is aimed at evaluating clinical factors and the microbiome in a cohort of about 900 individuals with various metabolic phenotypes in order to elucidate the interrelationship between the microbiome, obesity, and metabolic disorders, Second Genome said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.